Picture of person typing on laptop with programming code visible on the laptop screen

World class computing and information science research at Strathclyde...

The Strathprints institutional repository is a digital archive of University of Strathclyde's Open Access research outputs. Strathprints provides access to thousands of Open Access research papers by University of Strathclyde researchers, including by researchers from the Department of Computer & Information Sciences involved in mathematically structured programming, similarity and metric search, computer security, software systems, combinatronics and digital health.

The Department also includes the iSchool Research Group, which performs leading research into socio-technical phenomena and topics such as information retrieval and information seeking behaviour.

Explore

Anti-gonadotropin releasing hormone vaccines and their potential use in the treatment of hormone-responsive cancers

Ferro, Valerie A. and Stimson, William H. (1999) Anti-gonadotropin releasing hormone vaccines and their potential use in the treatment of hormone-responsive cancers. BioDrugs, 12 (1). pp. 1-12. ISSN 1179-190X

Full text not available in this repository. Request a copy from the Strathclyde author

Abstract

Gonadotropin-releasing hormone (GnRH) and its analogues have been used clinically to treat a range of hormone-dependent conditions. It is often necessary for large, toxic and expensive drug doses to be administered. Improvements in drug delivery have necessitated new developments in formulation, but these in turn can induce new adverse effects. Immunological neutralisation of GnRH has been examined as a less toxic and cheaper replacement therapy, and has been studied closely in different animal species. However, only a few clinical trials have been carried out with respect to hormone-dependent cancers. Based on clinical trials of the free peptide drug in cancer patients, it would appear that there is an increasing trend towards using GnRH and its analogues in adjuvant therapy and that antibody-based GnRH neutralisation will have a role in this treatment regimen.